Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Internal Audit Disclosure Highlights FDA Policy Exceptions

This article was originally published in The Gold Sheet

Executive Summary

FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.

You may also be interested in...



FDA Focuses Latest Warnings on Accountability and Root Cause

Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?

FDA Focuses Latest Warnings on Accountability and Root Cause

Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?

Data Integrity Problems Continued to Surface in Recent Warning Letters

Recent GMP warning letters featured data integrity issues.

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel